Whole Tumor Cell Vaccine Development for Breast Cancer

Whole tumor cell vaccines represent a cutting-edge approach in the realm of cancer immunotherapy, specifically targeting breast cancer. Unlike traditional vaccines that utilize specific antigens, whole tumor cell vaccines employ live or inactivated tumor cells to stimulate a comprehensive immune response. Alfa Cytology is committed to advancing the development of whole tumor cell vaccines for breast cancer.

Introduction to Whole Tumor Cell Vaccine

Tumor vaccines clonal expansion of tumor-reactive T-cells, and they may overcome the heterogeneity o have been considered promising cancer immunotherapy tools by harnessing host immunity to fight tumor cells. Antigens, adjuvants, and preparations are three very important components of cancer vaccines. Antigens are the most important components of cancer vaccines. Choosing appropriate antigens is the most important step in designing vaccines, and whole tumor cells are the best source of antigens for preparing cancer vaccines. Whole-cell vaccinations demonstrate pan-spectra of tumor antigens inducing multi-f tumor cells. The cornerstone of whole-tumor cell vaccines is to attenuate tumor cells to avoid tumor development (X-ray irradiation, freeze-thaw cycles, etc.) and maintain immunogenicity by retaining cancer-associated epitopes.

Fig.1Schematic representation of the sources of tumor antigens used to prepare cancer vaccines. (Diao L, et al., 2023)

Our Services

Alfa Cytology has professional knowledge and experienced teams in BC vaccine design, engineering, characterization, evaluation, animal models, and development. We will take careful scientific consideration based on the specific characteristics and clinical purpose of your BC vaccine candidate to ensure the most appropriate solution for your project development. Our services include:

• BC vaccine discovery
  We uniquely combine BC therapeutics and immunology expertise for cancer vaccine design, tumor antigen identification, adjuvant candidate discovery, biomarker discovery and validation, and more. For each service, our scientific experts and skilled technical staff can provide our clients with strategic guidance to customize appropriate vaccine discovery options.

• 

  BC vaccine modification
  A number of different strategies are available to genetically modify BC tumor cells to make them more immunogenic, including the introduction of cytokine molecules, xenogeneic or immunogenic antigens, viral tumor lysates, and/or costimulatory molecules.
• BC vaccine characterization analysis
  Use a comprehensive approach to evaluate the carbohydrates, lipids, proteins and other components of vaccines, and use advanced technology platforms such as high-resolution mass spectrometry and nuclear magnetic resonance to carry out vaccine development and research, including vaccine stability studies and vaccine release testing.
• In vivo evaluation of BC vaccine
  Provide services such as pharmacology and toxicology testing (especially immunogenicity), efficacy monitoring, and construction of animal models most suitable for vaccine development to meet your needs for in vivo vaccine evaluation throughout the entire life cycle of vaccine development.

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC-related single-domain antibody development services and help in the treatment and diagnosis of BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.